ArticleJournal of vascular surgery. Venous and lymphatic disorders2026
One-year outcomes of mechanochemical ablation of incompetent saphenous veins using the Flebogrif device.
Article in Journal of vascular surgery. Venous and lymphatic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nonrotational mechano-chemical ablation with foam injection - another option for nonthermal nontumescent incompetent truncal vein treatment.Journal of vascular surgery. Venous and lymphatic disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFlebogrif introduces a novel mechanochemical ablation technique for the treatment of incompetent saphenous veins. However, studies evaluating its efficacy as a relatively new treatment technique remain scarce. This study aimed to evaluate 1-year clinical outcomes after its application.
methodsWe conducted a retrospective analysis of 61 patients with 105 incompetent great saphenous veins who underwent treatment with Flebogrif. Primary outcomes included anatomical success rates at 1, 6, and 12 months post procedure, with secondary outcomes including adverse events, pain scores, Revised Venous Clinical Severity score, Chronic Venous Insufficiency Quality of Life Questionnaire scores, time to resumption of normal activities, and foam sclerosant dosage.
resultsThe anatomical success rates were 100% at 1 month, 98.4% at 6 months, and 95.4% at 12 months. Adverse events were mild, with no severe complications such as paresthesia or deep vein thrombosis. Flebogrif facilitated the treatment of multiple veins without related adverse events, averaging a foam sclerosant dosage of 17.70 ± 6.13 mL per procedure. Both the Revised Venous Clinical Severity score and Chronic Venous Insufficiency Quality of Life Questionnaire scores demonstrated a significant reduction from baseline.
conclusionsFlebogrif is a safe and effective technique for the treatment of multiple incompetent saphenous veins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.